The global Liquid Biopsy Market is projected to grow from USD 4.03 billion in 2025 to USD 7.05 billion by 2030, at a CAGR of 11.8% during the forecast period. The market is witnessing robust growth due to the rising global incidence of cancer and increasing demand for non-invasive, accurate, and efficient diagnostic solutions.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350
Liquid biopsy is emerging as a transformative tool in oncology, offering real-time insights into tumor progression through minimally invasive procedures. Technological advancements in next-generation sequencing (NGS) and digital PCR have significantly enhanced the sensitivity, specificity, and clinical utility of liquid biopsy assays. Additionally, global cancer awareness initiatives and national screening programs are driving the adoption of early detection methods, further fueling market growth.
NGS-Based Multi-Gene Analysis Dominates Technology Segment
By technology, the multi-gene parallel analysis segment using NGS accounted for the largest share of the liquid biopsy market in 2024. This dominance is attributed to NGS’s ability to simultaneously analyze multiple genetic alterations, enabling comprehensive molecular profiling with high precision.
The high-throughput capabilities and flexibility of NGS make it particularly suitable for clinical applications such as therapy selection, disease monitoring, and detection of complex genomic changes. Its growing integration into personalized medicine and routine diagnostic workflows continues to strengthen its market position.
Cancer Applications Drive Market Growth
By application, the cancer segment held the largest share of the liquid biopsy market in 2024. This is primarily driven by the increasing prevalence of cancer and expanding research efforts in oncology.
Liquid biopsy technologies enable real-time monitoring of tumor dynamics, detection of minimal residual disease, and identification of actionable mutations. These advantages help overcome the limitations of traditional tissue biopsies, such as invasiveness and inability to capture tumor heterogeneity, thereby accelerating their adoption in cancer diagnosis and management.
Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=13966350
North America Leads the Global Market
North America accounted for the largest share of the liquid biopsy market in 2024, supported by a well-established healthcare infrastructure, advanced diagnostic capabilities, and a strong network of specialized cancer care centers.
The region benefits from a highly skilled medical workforce and widespread adoption of innovative diagnostic technologies. These factors facilitate the integration of liquid biopsy into routine clinical practice, ensuring improved patient access and better healthcare outcomes.
Competitive Landscape
Key players in the liquid biopsy market include Natera, Inc. (US), QIAGEN (Netherlands), Guardant Health (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), GRAIL, Inc. (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), and Sysmex Corporation (Japan).
These companies are focusing on expanding their genomic testing capabilities, advancing sequencing technologies, and strengthening strategic collaborations to enhance their market presence and drive innovation.
